Výsledky vyhledávání - "B. Mirtsching"

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

Autor: Shirin Khambata-Ford, Heinz-Josef Lenz, Philip Stella, Eric K. Rowinsky, Nozar Azarnia, Robert J. Mayer, Allen Lee Cohn, Eric Van Cutsem, David J. Mauro, Andrew William Pippas, B. Mirtsching, Zenta Tsuchihashi, Philip J. Gold

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(30)

Purpose This multicenter study evaluated the antitumor activity of cetuximab, an immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in metastatic colorectal carcinoma (CRC) refractory to irinotecan, oxaliplatin, and a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76d19055690bdd3116db315b3ddde693
https://pubmed.ncbi.nlm.nih.gov/17050875

Zobrazit plný text záznamu

Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04–012)

Autor: T. Cosgriff, M. Min, T. Chidiac, M. Keaton, G. Harker, B. Mirtsching

Publikováno v: Journal of Clinical Oncology. 26:1118-1118

1118 Background: Nab-paclitaxel for injectable suspension given weekly has shown activity in patients whose metastatic breast cancer was refractory to taxane therapy. The purpose of this phase II s...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::65a4a4ad53944b3c85a46b6ed96b87f3
https://doi.org/10.1200/jco.2008.26.15_suppl.1118

Zobrazit plný text záznamu

A phase 2 study to evaluate the efficacy of darbepoetin-alfa administered using an extended dose schedule versus weekly dosing in cancer patients with chemotherapy-induced anemia

Autor: Tom Lillie, L. Yee, Ronald Burkes, Peter T. Silberstein, Timothy Rearden, Lee S. Schwartzberg, B. Mirtsching, Veena Charu, H. Lam

Publikováno v: Journal of Clinical Oncology. 25:19501-19501

19501 Background: Chemotherapy-induced anemia (CIA) can be effectively treated with darbepoetin alfa (DA) using different dosing schedules. Since chemotherapy (CTX) regimens involve various dosing schedules, the ability to synchronize DA dose with CT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1477ec1443e2e12d2bd7b9ad6542385f
https://doi.org/10.1200/jco.2007.25.18_suppl.19501

Zobrazit plný text záznamu

A phase II study of XL999 in patients (pts) with NSCLC

Autor: M. Wertheim, R. J. March, S. Modi, B. Mirtsching

Publikováno v: Journal of Clinical Oncology. 25:18112-18112

18112 Background: XL999 is a potent spectrum-selective inhibitor of receptor tyrosine kinases including VEGFR2/KDR, FGFR1/3, PDGFR-β, FLT3, RET, KIT, & SRC. A Ph 1 clinical study in pts w/advanced malignancies evaluating weight-based (0.2 - 6.4 mg/k

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97e785fa03a25da1a32c01795c606997
https://doi.org/10.1200/jco.2007.25.18_suppl.18112

Zobrazit plný text záznamu

First-line treatment of metastatic breast cancer with weekly abraxane (nab-paclitaxel: a 130 nm albumin-bound paclitaxel particle): A preliminary analysis of the phase II international oncology network ION-04–012 study

Autor: T. Chidiac, T. Cosgriff, B. Mirtsching

Publikováno v: Journal of Clinical Oncology. 24:10707-10707

10707 Background: Abraxane (paclitaxel protein-bound particles) by intravenous weekly administration schedule has been demonstrated to be active and well tolerated in patients with metastatic breast cancer (MBC) refractory to prior taxane therapy. Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c6c7514acf3995764ae7c621fa69676
https://doi.org/10.1200/jco.2006.24.18_suppl.10707

Zobrazit plný text záznamu

Final results of a large, community-based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy

Autor: M. Rader, Howard Ozer, B. Mirtsching, Lyndah Dreiling, B. Ding, D. Truscinski

Publikováno v: Journal of Clinical Oncology. 24:8569-8569

8569 Background: Neutropenia is the major dose-limiting complication of myelosuppressive chemotherapy (CT). The Awareness of Neutropenia in CT (ANC) Study Group has prospectively documented cycle 1 febrile neutropenia (FN) in 8% of patients (pts) rec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::36622cce1e3ff70c5e93552aa8202eb1
https://doi.org/10.1200/jco.2006.24.18_suppl.8569

Zobrazit plný text záznamu

Efficacy of darbepoetin alfa in chemotherapy-induced anemia in gastrointestinal cancers

Autor: G. Rossi, Dianne Tomita, Douglas W. Blayney, Saroj Vadhan-Raj, B. Mirtsching

Publikováno v: Journal of Clinical Oncology. 23:8210-8210

8210 Background: Chemotherapy-induced anemia (CIA) is common in colorectal (CRC) and other gastrointestinal (GI) cancer patients (pts). Darbepoetin alfa (DA) has been shown to increase hemoglobin (...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::287b97a7524df02e5187f5af0cd3326f
https://doi.org/10.1200/jco.2005.23.16_suppl.8210

Zobrazit plný text záznamu

Impact of 1st and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy: Preliminary results of FIRST, a prospective community-based study

Autor: B. Ding, B. Mirtsching, M. Rader, Roger Dansey, Howard Ozer

Publikováno v: Journal of Clinical Oncology. 23:8118-8118

8118 Background: Most alterations to chemotherapy (CT) dose and schedule are due to neutropenic events, which mostly occur in the 1st cycle. The ANC registry study has prospectively documented 1st ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6db6c2616ce844b8fbccb4d55e09f8b8
https://doi.org/10.1200/jco.2005.23.16_suppl.8118

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání